Sanjivani Parenteral FY26 PAT ₹66.94 mn

Sanjivani Parenteral reported FY26 consolidated PAT of ₹66.94 mn with a 9.60% margin on total income of ₹697.56 mn.
The company commenced commercial production at its new IV Fluid Infusion Plant in Pune, strengthening manufacturing capabilities.
Exports contributed 78.50% of FY26 revenue, with core markets (CIS, Middle East, Africa, Latin America) accounting for 77.01%.
Tablets segment revenue grew 7.5% YoY to ₹279.14 mn, while Injectables remained the largest contributor at 53.45%.